Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer ... even minimal asbestos exposure. Click here to read the complete story , just ... Cancer Center, Cedars Sinai Medical Center, and New York University exposed mice with a ...
(Date:7/3/2015)... ... , ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod ... . To be held from March 4th - 6th, the 2016 (a previous announcement ... Dallas. , Designed to take participants from the basic training and fundamentals of nasal ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national president ... executive search firms in the healthcare industry, B. E. Smith has recently placed ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national chief nursing officer recruitment for Jane Phillips Medical Center ... industry, B. E. Smith has recently placed more than 1,000 healthcare executives into ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy ... injured bicyclists and practical points of investigating these types of cases. , Each ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2
... veterans , , TUESDAY, March 24 (HealthDay News) -- Exposure ... to have triggered abnormal responses in the brains of ... the discovery could lead to new diagnostic tests and ... , The study, from the University of Texas Southwestern ...
... Omega-3 fatty acids appear protective against advanced prostate ... genetic variant in the COX-2 gene, according to a ... of the American Association for Cancer Research. , "Previous ... is one of the first studies to show protection ...
... the threat of tuberculosis and the toll it takes on ... , The TB-HIV co-infection crisis is twice as big ... there were at least 1.37 million cases of HIV-positive TBor ... the previous WHO estimates. , "A global health catastrophe ...
... Inc. (NYSE: CNO ) today announced that ... senior secured credit agreement. Banc of America Securities ... the amendment. The amendment, which does not seek ... repayment schedule, is expected to provide for, among other ...
... Cancer Action Network, the American Heart Association, the American ... Senator Frank Lautenberg of New Jersey,s call for the ... immediately remove e-cigarettes from the market. FDA officials ... the past few weeks saying that e-cigarettes are "new ...
... shown that an innovative anti-microbial catheter could vastly improve ... dialysis patients. , Results of a study published in ... the catheter has the potential to ward off attack ... Ambulatory Peritoneal Dialysis (CAPD) patients from infections for up ...
Cached Medicine News:Health News:Gulf War Syndrome May Stem From Chemical Exposure 2Health News:Alarming new data shows TB-HIV co-infection a bigger threat 2Health News:Conseco Seeks Amendment of Its Credit Facility 2Health News:Conseco Seeks Amendment of Its Credit Facility 3Health News:Conseco Seeks Amendment of Its Credit Facility 4Health News:Statement of the American Cancer Society Cancer Action Network, American Heart Association, American Lung Association and the Campaign for Tobacco-Free Kids 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 2Health News:Anti-microbial catheter to cut infection risk for dialysis patients 3
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... Mexique, July 3, 2015 ... les épidémies que sont l,hypertension, le diabète et ... de plateformes éducatives gratuites et d,une conférence majeure ... http://photos.prnewswire.com/prnh/20150630/227033 ) , Les ... ligne , Prendre en charge l,hypertension en ...
(Date:7/3/2015)... HUATULCO, Mexico , July 3, 2015 ... targeting the epidemics of hypertension, diabetes and thyroid disorders ... online educational platforms and a major conference dedicated to ... Manage Diabetes Online , Manage Hypertension ... each developed and operated by EXCEMED - ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 2Lutter contre trois maladies chroniques majeures en Amérique latine grâce à la formation médicale 3Combating Three Major Chronic Diseases in Latin America With Medical Education 2
... March 5, 2012  Sono-Tek Corporation (OTC BB: SOTK.pk) completed ... record preliminary results. Sales were approximately $12,000,000, an increase ... income is expected to be approximately $1,200,000, an increase ... $594,000 and above our goal of $1,000,000. Sono-Tek will ...
... 5, 2012  CVS Caremark (NYSE: CVS ) today ... and chief medical officer of the company, has been named ... , an independent commission that will assess how physicians ... care. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )   ...
Cached Medicine Technology:Sono-Tek Announces Record Year End Results 2CVS Caremark's Chief Medical Officer Troyen Brennan is Named to the National Commission on Physician Payment Reform 2
... is the Bard Kugel Patch, which is constructed ... two layers create a positioning pocket, which is ... position. On the other side is a barrier ... "memory recoil ring," which causes the patch to ...
... Bard mesh has become the standard against ... mesh was used by Dr. Irving Lichtenstein ... repair many years ago. Lichtenstein describes Bard ... for permanent reinforcement of hernia repair. As ...
... Visilex mesh is the first polypropylene ... repair. Visilex mesh directly addresses the ... More specifically, it delivers maximum visibility, ... profile after insertion through the trocar.,Visilex ...
... mesh is a three-dimensional, anatomically formed prosthesis ... Bard 3DMax mesh has been designed based ... the inguinal canal. The result is a ... Bard 3DMax product is constructed of Bard ...
Medicine Products: